Oxford BioMedica plc, a world leader in the development and application of gene-based therapeutics using advanced gene delivery, will today present data at the Gene Therapy Policy Conference organised by the Recombinant DNA Advisory Committee of the US National Institute of Health (NIH). Oxford BioMedica's Chief Executive, Professor Alan Kingsman, will describe the Company's LentiVectorT programme including its proprietary PEGASUST system for efficient gene transfer to the brain.

Professor Kingsman commented, "We are the only European company that has been invited to talk at this meeting and it is this meeting which will establish the US policy framework for clinical trials using lentiviral vectors. These potent new gene transfer vectors are expected to have a dramatic impact on gene therapy procedures, particularly for the treatment of AIDS and neurodegenerative diseases."

Oxford BioMedica's invitation to present to the Recombinant DNA Advisory Committee is in recognition of the Company's pre-eminence in the field of lentiviral vectors for gene therapy.

Notes to Editors:

1. Oxford BioMedica: established in 1995, specialises in the development and application of gene-based therapeutics using advanced gene delivery technologies for the treatment of disease in the areas of: oncology, viral infection, neurobiology and genetic deficiency.
Oxford BioMedica plc was floated on the UK Alternative Investment Market of the London Stock Exchange in December 1996. The Company recently announced a placing and rights issue to raise £6 million (before expenses). These funds will provide the necessary funds for the continued development of the Group's candidate products and allow Oxford BioMedica to proceed with its first clinical trials due to start in the 4th Quarter 1998.